Criteria
| Eligible Active Ingredient: | Emedastine. As eyedrops not exceeding 0.05% |
| With Effective From: | 1-Jun-17 |
| Indication Permitted: | Short-term treatment of signs and symptoms of allergic conjunctivitis |
| Maximum Daily Dose: | One drop into the affected eye twice daily |
| Maximum Supply per Transaction: | 5ml |
| Minimum Age of User: | 3 years |
| Patient Information Leaflet from HSA/PSS: | Download PIL (Link to HSA website) |
Mechanism of Action of Emedastine
Emedastine is a relatively selective, histamine H1 antagonist. In vitro examinations of emedastine’s affinity for histamine receptors demonstrate relative selectivity for the H1 histamine receptor. In vivo studies have shown concentration-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration. Emedastine appears to be devoid of effects on adrenergic, dopaminergic and serotonin receptors.
Additional Information of Emedastine
| Pharmacology Class: | Decongestants And Antiallergics |
| Therapeutic Class: | Ophthalmologicals |
| Chemical Class: | Other Antiallergics |
| Synonyms: | 1-(2-Ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1H-benzoimidazole | 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole | 1-[2-(Ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole | Emedastina | Emedastinum |
Show All HSA-registered therapeutic products granted exemption to supply without prescription
References
HSA-Registered Products Containing Emedastine As eyedrops not exceeding 0.05%
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.